Legal & General Group PLC Cytom X Therapeutics, Inc. Transaction History

Legal & General Group PLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$1.53 - $2.89 $12,809 - $24,195	-8,372 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $843 - $1,478	316 Added 3.92%	8,372 $23,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $44,396 - $84,778	-11,472 Reduced 58.75%	8,056 $35,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $42,949 - $63,927	9,942 Added 103.71%	19,528 $99,000
Q2 2021 Aug 12, 2021	BUY	$6.33 - $9.91 $5,507 - $8,621	870 Added 9.98%	9,586 $60,000
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $13,206 - $18,009	2,001 Added 29.8%	8,716 $68,000
Q3 2020 Nov 13, 2020	SELL	$6.55 - $8.83 $12,752 - $17,192	-1,947 Reduced 22.48%	6,715 $44,000
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $2,878 - $5,694	389 Added 4.7%	8,662 $72,000
Q1 2020 May 14, 2020	SELL	$3.61 - $8.6 $9,201 - $21,921	-2,549 Reduced 23.55%	8,273 $63,000
Q4 2019 Feb 13, 2020	BUY	$5.17 - $8.91 $8,907 - $15,351	1,723 Added 18.94%	10,822 $90,000
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $7,077 - $8,637	757 Added 9.07%	9,099 $102,000
Q4 2018 Feb 15, 2019	BUY	$12.69 - $18.61 $16,573 - $24,304	1,306 Added 18.56%	8,342 $126,000
Q3 2018 Nov 20, 2018	BUY	$18.04 - $26.41 $16,849 - $24,666	934 Added 15.31%	7,036 $130,000
Q2 2018 Aug 10, 2018	BUY	$21.38 - $29.68 $21,037 - $29,205	984 Added 19.23%	6,102 $139,000
Q1 2018 May 17, 2018	SELL	$21.76 - $34.22 $46,305 - $72,820	-2,128 Reduced 29.37%	5,118 $146,000
Q4 2017 Feb 13, 2018	BUY	$19.0 - $23.09 $137,674 - $167,310	7,246	7,246 $155,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $77.8M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.